Biocytogen is excited to attend ARDD 2026 from October 1st - 3rd in Boston, MA. This meeting kicks off the beginning of Boston Longevity Week, an eleven day series of premier conferences, hackathons, and networking opportunities. Visit us at booth #9 to learn how our humanized and knockout mouse models support studies of aging mechanisms and diseases, as well as accelerate anti-aging therapeutic development.
What is ARDD 2026?
With the global elderly population growing at an unprecedented rate, age related diseases are creating significant healthcare challenges. The Aging Research & Drug Discovery (ARDD) Meeting will aim to address these concerns through understanding the biology of aging and translating scientific discoveries into new therapeutic treatments. The three day event will bring together over 1,000+ attendees and feature forums and talks covering Longevity Medicine, AI in Drug Discovery, Pet and Animal Longevity, and Virtual Aging Cell.
Event Overview
Date: October 1st - 3rd, 2026
Venue: David Rubenstein Treehouse at Harvard University, 20 Western Ave, Boston, MA 02134
Event Schedule
For more information, please refer to the event program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
